Anixa Biosciences and Cleveland Clinic report positive Phase 1 data for breast cancer vaccine

Anixa Biosciences Inc

Phase 1 trial of triple-negative breast cancer vaccine showed antigen-specific T cell responses at all dose levels.
Trial funded by U.S. Department of Defense; Anixa is exclusive worldwide licensee from Cleveland Clinic.
Participants were tumor-free women with history of TNBC, curatively treated, at high risk of recurrence.
Phase 1a study evaluates safety, MTD, and immune response; not designed to measure recurrence prevention.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.